Ensysce Biosciences' Lynn Kirkpatrick to Become COO as James Morrisson Becomes CEO

What happened

Ensysce Biosciences plans a leadership change immediately after its December 14, 2026 annual meeting: CEO Lynn Kirkpatrick is set to become chief operating officer, and President James Morrisson is set to become CEO. Kirkpatrick’s amended employment letter says taking the COO role will not trigger severance obligations.

Confirmed

Global impact / market context

The change shifts the company’s top executive role to Morrisson while retaining Kirkpatrick as COO, potentially preserving her experience in drug discovery and development. The employment-letter amendment also removes severance obligations triggered by her accepting the new role, which may limit transition-related costs.

Analyst inference

The article gives no financial terms, business outlook, or market reaction, so it does not establish a direct change to revenue, costs, or cash available. The leadership transition could nevertheless affect investor views of execution and continuity, especially if the meeting date changes.

Analyst inference

What to watch

1. Confirm whether the annual meeting occurs on December 14, 2026; both executive role changes are scheduled immediately afterward and would be delayed if the meeting is delayed. Confirmed
2. Watch for company disclosure of Morrisson’s priorities as CEO, since the article does not state his plans or explain why he was selected for the role. Analyst inference
3. Check whether Will Chang resigns as a director following the meeting; the article says he intends to resign but provides no specific resignation date. Confirmed

Evidence

• Original source link unavailable